EFiled: Dec 19 2013 01:20PM EST

Transaction ID 54734445

Case No. 7387-VCN

OF THE STATE OF DELAWARE

JOHN W. NOBLE VICE CHANCELLOR 417 SOUTH STATE STREET DOVER, DELAWARE 19901 TELEPHONE: (302) 739-4397 FACSIMILE: (302) 739-6179

December 19, 2013

Daniel B. Rath, Esquire Landis Rath & Cobb LLP 919 N. Market Street, Suite 1800 Wilmington, DE 19801 Thomas M. Horan, Esquire Womble Carlyle Sandridge & Rice, LLP 222 Delaware Avenue, Suite 1501 Wilmington, DE 19801

Re: ReCor Medical, Inc. v. Warnking

C.A. No. 7387-VCN

Date Submitted: November 12, 2013

Dear Counsel:

Defendants Reinhard Warnking and Sound Interventions, Inc. (collectively, "SII") have renewed their application for injunctive relief¹ constraining Plaintiff ReCor Medical, Inc.'s ("ReCor") conduct in prosecuting (or not prosecuting) various patent applications (the "Transferred Intellectual Property") that were awarded to ReCor following trial of this action.² SII's application is brought under Court of Chancery Rule 62(c) while its appeal of that decision is pending. Its

¹ The parties were able to resolve the earlier application without the need for judicial intervention.

² ReCor Med., Inc. v. Warnking, 2013 WL 3760022, at *19 (Del. Ch. May 31, 2013, revised July 16, 2013).

ReCor Medical, Inc. v. Warnking

C.A. No. 7387-VCN

December 19, 2013

Page 2

understandable concern is that, if it prevails on appeal, the value or efficacy of the

Transferred Intellectual Property may be impaired by ReCor's acts in the interim.

SII objects to ReCor's amendments (made without advance notice to it) of

the Transferred Intellectual Property, a step which it asserts amounts to an

abandonment of important aspects of the pending patent applications. SII claims

that ReCor's actions were in response to the International Preliminary Report on

Patentability, not to any direct urging of the U.S. Patent Office, and thus not

immediately necessary. SII also accuses ReCor of having made certain admissions

regarding the patent applications which, if allowed to remain in the record, would

likely affect the patentability of the Transferred Intellectual Property.

ReCor's conduct—if it is successful on appeal—will not have caused any

harm to SII because SII will have no interest in the Transferred Intellectual

Property. If ReCor does not prevail on appeal, however, SII will be confronted

with the challenge of undoing the consequences of ReCor's conduct. SII wants

mandatory injunctive relief requiring ReCor to restore the status quo before the

recent amendments to the patent applications and statements in the application

record. That would not merely require a simple ministerial step. It would require

Page 3

something of a sustained dialogue with the U.S. Patent Office. Moreover, the

Court is not in a good position to assess whether ReCor was justified in its

decisions regarding the Transferred Intellectual Property. Fortunately, if SII

regains the Transferred Intellectual Property, it will be able to seek to amend the

patent applications and to restore the claims as they existed before ReCor's recent

amendments.³ Similarly, the admissions can be expunged.⁴ In short, although

there will be delay and inconvenience, the potential harm is not irreparable.

Briefing of the appeal before the Delaware Supreme Court is almost

complete. Any further delay will be relatively minimal, and it seems unlikely that

ReCor, even if properly motivated, could achieve all that SII seeks in the time

available.

Thus, SII's application for mandatory injunctive relief is denied.

Nevertheless, SII has raised a substantial issue about the management of the

patent application process by ReCor. While the rights to the Transferred

Intellectual Property are at issue on appeal, SII's expectancy should not be subject

⁴ *Id.* 7, 13.

_

³ Transcript of Oral Arg. (Nov. 12, 2013) 11, 13-14.

Page 4

to ReCor's whims. One of the primary problems generated by ReCor's conduct

may be attributed to its failure to give timely notice to SII of its decision to amend

the patent applications. That is the type of harm as to which SII should be spared

the risk, if possible. Prospective relief, especially because it appears that there will

be no corresponding material cost to ReCor and thus the balancing of potential

harms favors SII, is appropriate. Accordingly, ReCor shall make no further

amendments to the Transferred Intellectual Property or take any other steps likely

to cause adverse consequences to the Transferred Intellectual Property without

fourteen-calendar-day advance written notice thereof to SII. That should provide

SII with sufficient opportunity to protect its interests.

In addition, as offered by ReCor,⁵ it shall promptly inform SII by written

notice of the deadline to submit a continuation application for the Transferred

Intellectual Property to the U.S. Patent Office while the appeal is pending. It has

been suggested that the deadline may not be scheduled until after the appeal has

been resolved, which would render this requirement moot. But, were that not the

case, SII should take comfort in being provided with prompt notice. Should the

⁵ ReCor's Resp. in Opp'n to Mot. for Inj. 9.

ReCor Medical, Inc. v. Warnking

C.A. No. 7387-VCN

December 19, 2013

Page 5

deadline happen to fall before the appeal is decided, the proper course of action

may have to be determined in the future.

SII also seeks reimbursement of fees paid to ReCor to maintain the

Transferred Intellectual Property and attorneys' fees for this renewed application

(and the earlier application). SII has not demonstrated why reimbursement is

warranted, as the parties' agreement, subject to the additional disclosures required

by this order, continues to govern ReCor's prosecution of the Transferred

Intellectual Property. Because the present application is generally denied, the

shifting of attorneys' fees for it and the earlier application is also inappropriate.

Finally, SII seeks a lifting of the injunction placed on its use of the non-

public technology in the Transferred Intellectual Property by the Court's post-trial

judgment.⁶ SII contends that ReCor's recent acts are recognition that at least some

of the technology is prior art and thus not an asset it could have acquired. This

argument may have merit, but SII has not demonstrated that the Court presently

-

⁶ See ReCor Med., Inc., 2013 WL 3760022, at *19.

ReCor Medical, Inc. v. Warnking C.A. No. 7387-VCN December 19, 2013 Page 6

has jurisdiction to lift the injunction while it is subject to appeal. Thus, this request is denied.⁷

IT IS SO ORDERED.

Very truly yours,

/s/ John W. Noble

JWN/cap

cc: Register in Chancery-K

⁷ ReCor has sought an award of its attorneys' fees and expenses as the prevailing party in this action. Resolution of that application should await disposition of SII's appeal.